Open Access

Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis

  • Authors:
    • Yan-Ling Bi
    • Pei-Yan Mi
    • Shi-Jun Zhao
    • Heng-Ming Pan
    • Hui-Juan Li
    • Fei Liu
    • Lu-Rong Shao
    • Hui-Fang Zhang
    • Pu Zhang
    • Shi-Liang Jiang
  • View Affiliations

  • Published online on: March 29, 2017     https://doi.org/10.3892/ijmm.2017.2940
  • Pages: 1255-1261
  • Copyright: © Bi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tumor angiogenesis plays a crucial role in tumor growth, progression and metastasis, and suppression of tumor angiogenesis has been considered as a promising anticancer strategy. Salinomycin (SAL), an antibiotic, displays novel anticancer potential against several human cancer cells in vitro and in vivo. However, little information concerning its anti-angiogenic properties is available. Therefore, the anti‑angiogenic effect of SAL and the underlying mechanism in human glioma were evaluated in the present study. The results indicated that SAL treatment significantly inhibited human umbilical vein endothelial cell (HUVEC) proliferation, migration, invasion and capillary-like tube formation. Further investigation on intracellular mechanisms showed that SAL markedly suppressed FAK and AKT phosphorylation, and downregulated vascular endothelial growth factor (VEGF) expression in HUVECs. Pretreatment of cells with a PI3K inhibitor (LY294002) and FAK inhibitor (PF562271) markedly enhanced SAL-induced inhibition of HUVEC proliferation and migration, respectively. Moreover, U251 human glioma xenograft growth was also effectively blocked by SAL treatment in vivo via inhibition of angiogenesis involving FAK and AKT depho­sphorylation. Taken together, our findings validated that SAL inhibits angiogenesis and human glioma growth through suppression of the VEGF-VEGFR2-AKT/FAK signaling axis, indicating the potential application of SAL for the treatment of human glioma.
View Figures
View References

Related Articles

Journal Cover

May-2017
Volume 39 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bi Y, Mi P, Zhao S, Pan H, Li H, Liu F, Shao L, Zhang H, Zhang P, Jiang S, Jiang S, et al: Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis. Int J Mol Med 39: 1255-1261, 2017
APA
Bi, Y., Mi, P., Zhao, S., Pan, H., Li, H., Liu, F. ... Jiang, S. (2017). Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis. International Journal of Molecular Medicine, 39, 1255-1261. https://doi.org/10.3892/ijmm.2017.2940
MLA
Bi, Y., Mi, P., Zhao, S., Pan, H., Li, H., Liu, F., Shao, L., Zhang, H., Zhang, P., Jiang, S."Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis". International Journal of Molecular Medicine 39.5 (2017): 1255-1261.
Chicago
Bi, Y., Mi, P., Zhao, S., Pan, H., Li, H., Liu, F., Shao, L., Zhang, H., Zhang, P., Jiang, S."Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis". International Journal of Molecular Medicine 39, no. 5 (2017): 1255-1261. https://doi.org/10.3892/ijmm.2017.2940